ClinicalTrials.gg
RecruitingNCT06989775Updated Oct 7, 2026

BoxX-NoAF Clinical Trial

An interventional study of Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System in Post Operative Atrial Fibrillation and Atrial Fibrillation, Postoperative, sponsored by AtriCure, Inc.. Recruiting at 37 sites in 2 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by AtriCure, Inc. · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 7, 202610 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atrial Fibrillation by AtriCure, Inc. — 2 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · AtriCure, Inc..

Planned enrollment
Largest of 23
960 · median 53
Started
2025
the only one that year
No phase
16 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Atrial Fibrillation by AtriCure, Inc., this one has the largest planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 16 with no phase, and was the 27th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 27 studies in Atrial Fibrillation by AtriCure, Inc. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atrial Fibrillation by AtriCure, Inc., or all of them as a file.
02

Study summary

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.

03

Conditions studied

  • Post Operative Atrial Fibrillation
  • Atrial Fibrillation, Postoperative

Browse trials for

Keywords

  • Post operative AF
  • Clinical AF
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned and clinically indicated for cardiac surgical procedure requiring cardiac bypass and opening of the pericardium
  • Age ≥ 65 years and CHA2DS2-VASc ≥ 3

Exclusion criteria

Exclusion Criteria:

  • Documented history of atrial fibrillation or atrial flutter anytime prior to the cardiac surgery
  • Prior procedure involving opening the pericardium or entering the pericardial space
  • Patients undergoing off-pump surgery
  • Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
  • Presence of a permanent pacemaker
  • Infiltrative cardiomyopathies (i.e. amyloidosis)
  • Planned cardiac surgical procedure using non-sternotomy approaches
  • Patients whose planned procedure is a heart transplant or implantation of any long-term ventricular assist devices
  • Presence of ventricular arrhythmia
  • Active endocarditis
  • Class IV heart failure symptoms
  • Preoperative need for an intra-aortic ballon pump or intravenous inotropes
  • Active systemic infection at the time of cardiac surgery requiring antibiotics
  • Known allergy to Nitinol or nickel sensitivity
  • Known medical condition with expected survival of less than 1 year
  • Other comorbidities that in the Investigator's opinion make the subject unsuitable candidate to complete the protocol required intervention or visits
  • Current enrollment in an investigation or trial or an devices or investigational drug that would interfere with this trial
  • Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
  • Pregnancy
  • Known severe symptomatic carotid disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Treatment

    Index cardiac surgery + Ablation + Left Atrial Appendage Exclusion with AtriClip

    Device: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System

  • No intervention
    Control

    Index cardiac surgery only

Interventions

  • DeviceIsolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System

    Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    The occurrence of clinically relevant post operative AF (POAF)

    Time frame: 30 days post index cardiac surgical procedure

  2. Primary Safety Endpoint

    The composite of the following events: * All cause Mortality * Reoperation * Deep sternal wound infection * Permanent stroke * Prolonged ventilation * Renal failure * 30-day readmission * Atypical left atrial flutter * Phrenic nerve palsy * Major Bleeding

    Time frame: 30 days post index cardiac surgical procedure

Secondary outcomes

  1. Powered Secondary Effectiveness Endpoint

    The time to first occurrence of clinical atrial fibrillation from 30 days after index cardiac surgical procedure through 3-years

    Time frame: 3 years post index cardiac surgical procedure

07

Study locations

35 of 37 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 16 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 25, 2025
StartActual
Oct 24, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added
Show 10 added (9 United States, 1 Canada)
  • Honor Health · Scottsdale, United States
  • Adventist Health St. Helena · St. Helena, United States
  • Naples Comprehensive Health · Naples, United States
  • University of Michigan · Ann Arbor, United States
  • BJC Healthcare (Washington University) · St Louis, United States
  • Promedica Toledo Hospital · Toledo, United States
  • Centennial Medical Center · Nashville, United States
  • St David's HealthCare · Austin, United States
  • Methodist San Antonio · San Antonio, United States
  • Royal Columbian Hospital · New Westminster, Canada
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    10 sites added
    Show 10 added (9 United States, 1 Canada)
    • Honor Health · Scottsdale, United States
    • Adventist Health St. Helena · St. Helena, United States
    • Naples Comprehensive Health · Naples, United States
    • University of Michigan · Ann Arbor, United States
    • BJC Healthcare (Washington University) · St Louis, United States
    • Promedica Toledo Hospital · Toledo, United States
    • Centennial Medical Center · Nashville, United States
    • St David's HealthCare · Austin, United States
    • Methodist San Antonio · San Antonio, United States
    • Royal Columbian Hospital · New Westminster, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06989775
Lead sponsor
AtriCure, Inc.
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Oct 24, 2025
Primary completion
Feb 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

BoxX-NoAF Trial Inbox
Contact
BoxXNoAF@atricure.com
1 (513) 755-4100

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion